Journal of International Psychiatry

Abstract: Objective: To compare the effects of Ziprasidone and Olanzapine on glucolipid metabolism and cognitive function of patients with first-episode schizophrenia, and to analyze the possible mechanism of action. Methods: A total of 116 cases of patients with first-episode schizophrenia admitted to hospital from July 2014 to June 2015 were selected as the research objects and randomly divided into Ziprasidone group and Olanzapine group according to the odd or even number of the medical records, with 58 cases in each group. Patients in Ziprasidone group were given oral medication of Ziprasidone, and those in Olanzapine group were given oral medication of Olanzapine. After 4 months, the glucolipid metabolism, cognitive function and adverse reactions of the two groups were compared. Results: The levels of fasting blood-glucose (FBG), low-density lipoprotein cholesterol (LDL-C), T-cholesterol (TC) and triglyceride (TG) in Ziprasidone group were significantly lower than those in control group (P<0.05); the positive and negative syndrome scale (PANSS) score was significantly lower than that in control group, the Wechsler adult intelligence scale-revised (WAIS-RC) digital symbol score was significantly higher than that in Olanzapine group (P<0.05); the incidence rate of adverse reactions was 27.59% and significantly lower than 51.72% in control group (P<0.05). Conclusion: Ziprasidone can help to improve the clinical positive and negative symptoms of patients with first-episode schizophrenia, reduce glucolipid metabolism and adverse reactions and improve cognitive function.

Key words: first-episode schizophrenia; ziprasidone; olanzapine; glycolipid metabolism; cognitive function